STOCK TITAN
  1. Home
  2. Sec-filings
  3. BEAM
  4. [Form 4] Beam Therapeutics Inc. Insider Trading Activity

[Form 4] Beam Therapeutics Inc. Insider Trading Activity

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Beam Therapeutics Inc. CEO John M. Evans reported an automatic sale of 30,078 shares of common stock on April 1, 2026 at $24.58 per share. According to the disclosure, these shares were sold in a non-discretionary transaction solely to cover tax withholding obligations tied to previously granted restricted stock units under the company’s 2019 Equity Incentive Plan, pursuant to a Rule 10b5-1 trading plan adopted in May 2023. Following this transaction, Evans directly holds 1,047,205 shares and indirectly holds 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust, which total includes 616 shares acquired under the company’s amended and restated 2019 Employee Stock Purchase Plan on March 31, 2026.

Positive

  • None.

Negative

  • None.

Insights

CEO’s sale is automatic tax-related selling under a 10b5-1 plan.

The filing shows Beam Therapeutics CEO John M. Evans sold 30,078 shares of common stock at $24.58 on April 1, 2026. The footnote explains this was an automatic, non-discretionary sale to cover tax withholding on vested restricted stock units.

The sale occurred under a pre-established Rule 10b5-1 trading plan adopted on May 19, 2023, which indicates the timing was pre-planned rather than opportunistic. After the sale, Evans still directly holds 1,047,205 shares and indirectly holds 103,000 shares via a 2018 irrevocable trust.

This makes the transaction relatively small compared with his overall stake and largely mechanical in nature. The filing also notes an additional 616 shares acquired through the company’s employee stock purchase plan on March 31, 2026, underscoring ongoing equity participation alongside the tax-driven disposition.

Insider Evans John M.
Role CEO
Sold 30,078 shs ($739K)
Type Security Shares Price Value
Sale Common Stock 30,078 $24.58 $739K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 1,047,205 shares (Direct); Common Stock — 103,000 shares (Indirect, By John M. Evans, III 2018 Irrevocable Trust)
Footnotes (1)
  1. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023. Includes 616 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2026.
Shares sold 30,078 shares Open-market sale on April 1, 2026 to cover tax withholding
Sale price $24.58 per share Average price for 30,078 Beam Therapeutics common shares sold
Direct holdings after sale 1,047,205 shares Common stock directly owned by CEO after reported transaction
Indirect holdings after sale 103,000 shares Common stock held via John M. Evans, III 2018 Irrevocable Trust
ESPP acquisition 616 shares Shares acquired under Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2026
Rule 10b5-1 trading plan regulatory
"The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting"
2019 Equity Incentive Plan financial
"restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan"
Employee Stock Purchase Plan financial
"Includes 616 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2026."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Evans John M.
(Last)(First)(Middle)
C/O BEAM THERAPEUTICS INC.,
238 MAIN STREET
(Street)
CAMBRIDGE MASSACHUSETTS 02142
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/01/2026S(1)30,078D$24.581,047,205(2)D
Common Stock103,000IBy John M. Evans, III 2018 Irrevocable Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.
2. Includes 616 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2026.
By: /s/ Christine Bellon, Attorney-in-fact04/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Beam Therapeutics (BEAM) report for CEO John M. Evans?

Beam Therapeutics reported that CEO John M. Evans sold 30,078 shares of common stock at $24.58 on April 1, 2026. The filing states this was an automatic, non-discretionary sale to cover tax withholding obligations related to vested restricted stock units.

Was the BEAM CEO’s April 1, 2026 share sale discretionary or pre-planned?

The sale was described as non-discretionary and executed to cover tax withholding obligations. It was carried out under a Rule 10b5-1 trading plan adopted on May 19, 2023, indicating the timing and mechanics were pre-planned rather than a discretionary market-timing decision.

How many Beam Therapeutics shares does CEO John M. Evans hold after this Form 4?

After the reported transaction, John M. Evans directly holds 1,047,205 Beam Therapeutics shares. He also indirectly holds 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust, providing a total reported equity exposure well above the 30,078 shares sold for tax withholding.

What price per share did the BEAM CEO receive in the April 1, 2026 sale?

The filing shows an average sale price of $24.58 per Beam Therapeutics common share for the 30,078 shares sold. These proceeds were used to satisfy tax withholding obligations tied to vesting restricted stock units, rather than representing a discretionary liquidation of holdings.

What is the role of the Rule 10b5-1 trading plan in this BEAM insider sale?

The company disclosed that the sale was effected under a Rule 10b5-1 trading plan adopted on May 19, 2023. Such plans pre-arrange trades, helping demonstrate that the tax-related sale’s timing was scheduled in advance rather than based on inside information or near-term market expectations.

Did the BEAM CEO acquire any shares around the time of this sale?

Yes. A footnote states that Evans acquired 616 Beam Therapeutics shares under the amended and restated 2019 Employee Stock Purchase Plan on March 31, 2026. Those newly acquired shares are included in the 1,047,205 directly held shares reported after the tax-driven sale.